Securities code: 603259 Securities abbreviation: WuXi AppTec Announcement Number: Lin 2023-074
Wuxi WuXi AppTec New Drug Development Co., Ltd.
Announcement on the listing of the joint-stock company WuXi XDC Cayman Inc. on the main board of the Hong Kong Stock Exchange
The company’s board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
1. Overview of the listing of joint-stock companies
WuXi XDC Cayman Inc. (Wuxi XDC Cayman Inc., hereinafter referred to as “WuXi United”), a joint venture in which WuXi AppTec New Drug Development Co., Ltd. (hereinafter referred to as the “Company”) holds shares, in November 2023 Listed on the main board of The Stock Exchange of Hong Kong Limited (hereinafter referred to as the “Hong Kong Stock Exchange”) on the 17th, stock code: 2268. Details of WuXi United’s Hong Kong listing can be found on the information disclosure website of the Hong Kong Stock Exchange (www.hkexnews.hk).
2. Shareholding status
After the completion of WuXi United’s global offering, the company’s controlled subsidiary Shanghai Hequan Pharmaceutical Co., Ltd. will hold WuXi through its wholly-owned subsidiary STA Pharmaceutical Hong Kong Investment Limited. The number of shares of Helian is 400,000,000 shares, accounting for approximately 33.94% of the total share capital of Wuxi United after the issuance is completed. If WuXi United subsequently exercises all or part of its over-allotment option, the Company’s shareholding in WuXi United will be further diluted.
3. Accounting treatment and impact on WuXi United’s equity
In accordance with relevant regulations such as “Accounting Standards for Business Enterprises No. 2 – Long-term Equity Investment”, the Company classified the equity held by WuXi United as “long-term equity investment in associates” and listed it in “long-term equity investment”. After WuXi United is listed, the Company will still use the equity method to account for it. The actual impact of WuXi United’s listing on the company’s financial status will ultimately be determined by the conclusion of the relevant audit report. Investors are advised to pay attention to investment risk.
Special announcement.
Board of Directors of Wuxi WuXi AppTec New Drug Development Co., Ltd.
November 18, 2023
2023-11-17 18:27:58
#Announcement #Wuxi #WuXi #AppTec #Drug #Development #listing #jointstock #company #WuXi #XDC #Cayman #main #board #Hong #Kong #Stock #Exchange #Shanghai #Securities #News
